GRFS — Grifols SA
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1438569 ·
Last close
$7.87
Market Cap
$2.03B
52W High
$8.37
52W Low
$6.87
ADV30
826,519
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 1,874,000,000 | 704,000,000 | 329,000,000 | 154,000,000 | 20,090,000,000 | 513,000,000 | 12,110,000,000 |
| Mar 2026 | 1,700,000,000 | 620,000,000 | 249,000,000 | 73,000,000 | 20,078,000,000 | 702,000,000 | 12,231,000,000 |
| Dec 2025 | 1,981,660,000 | 686,841,000 | 275,377,000 | 98,250,000 | 19,712,000,000 | 801,000,000 | 12,109,000,000 |
| Jun 2025 | 1,891,131,000 | 743,795,000 | 349,541,000 | 117,063,000 | 19,767,159,000 | 558,691,000 | 12,169,006,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$1,245,092,000
Investing CF
$-526,031,000
Financing CF
$-1,658,785,000
CapEx
$-361,149,000
Dividends Paid
$-25,618,000
Buybacks
—
EPS Diluted TTM
$0.35
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$300,000,000
Inventory
$3,296,000,000
Receivables
$856,000,000
ST Investments
$23,000,000
EBIT TTM
$1,094,468,000
Pretax Income TTM
$631,565,000
Interest Exp TTM
$462,903,000
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$7,421,000,192
EBITDA
$1,645,230,976
Free Cash Flow
$572,923,392
Enterprise Value
$22,414,524,416
Total Cash
$537,000,000
Total Debt
$9,356,000,256
Shares Out
258,223,442
Trailing EPS
$0.75
Book Value
$4.57
ROE
6.9%
ROA
4.2%
Div Yield
3.43%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 7,524,000,000 | 1,251,000,000 | 402,000,000 | 19,712,000,000 | 12,109,000,000 | — | 1,047,000,000 |
| Dec 2024 | 7,212,000,000 | 1,155,000,000 | 157,000,000 | 21,405,000,000 | 12,799,000,000 | — | 902,000,000 |
| Dec 2023 | 6,592,000,000 | 718,000,000 | 42,000,000 | 20,992,103,000 | 13,478,408,000 | — | 217,000,000 |
| Dec 2022 | 6,063,967,000 | 678,958,000 | 185,035,000 | 21,229,584,000 | 13,253,455,000 | — | -1,427,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$1.43
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BHVN | Biohaven Ltd. | $2.03B | $13.50 | — |
| HRMY | Harmony Biosciences Holdings, Inc. | $2.04B | $35.24 | — |
| ZLAB | Zai Lab Ltd | $2.06B | $18.27 | — |
| PVLA | PALVELLA THERAPEUTICS, INC. | $1.99B | $139.04 | — |
| ZBIO | Zenas BioPharma, Inc. | $1.98B | $31.44 | — |
News headlines (Yahoo Finance, 1h cache)
FOXO TECHNOLOGIES INC.’S SUBSIDIARY VECTOR BIOSOURCE, INC. ENTERS INTO DEFINITIVE AGREEMENT TO ACQUIRE FOUR BLOOD COLLECTION CENTERS FROM GRIFOLS BIO SUPPLIES, INC.
2026-07-29 12:30 · Yahoo
Grifols (GRFS) Q2 2026 Earnings Call Transcript
2026-07-29 01:12 · Yahoo
Grifols SA (GRFS) (H1 2026) Earnings Call Highlights: Strong Biopharma Growth and Strategic ...
2026-07-29 01:01 · Yahoo
Grifols Q2 Earnings Call Highlights
2026-07-28 18:04 · Yahoo
Grifols (BME:GRF) Starts Phase 3 Trials As Undervalued Narrative Faces A Fresh Test
2026-07-28 17:09 · Yahoo
European Equities Traded in the US as American Depositary Receipts Start Week Marginally Higher in Monday Trading
2026-07-27 15:13 · Yahoo
European Equities Traded in the US as American Depositary Receipts Fall in Thursday Trading
2026-07-23 15:13 · Yahoo
European Equities Traded in the US as American Depositary Receipts Track Lower in Monday Trading
2026-07-20 15:13 · Yahoo
Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins
2026-07-16 12:00 · Yahoo
European Equities Traded in the US as American Depositary Receipts Advance Wednesday
2026-07-15 15:08 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.